Halozyme Therapeutics (HALO) - Long-Term Debt to Capital

Corporate emblem and logo of Halozyme Therapeutics (HALO)

Halozyme Therapeutics (HALO) specializes in developing drug delivery systems. This daily price chart reflects the impact of a strategy centered on licensing innovations to global behemoths, which minimizes regulatory risks. Returns are based on partner payments for the use of its oncology platform, reaching 12.51. The business relies on the legal protection of intellectual property in the US and Europe, remaining outside the zone of geopolitical conflicts.

Halozyme Inc. - HALO Long-Term Debt to Capital (period 07/04/2022 - 11/01/2026)

Analytical breakdowns for Halozyme Therapeutics

- stock value and consensus price forecast:
Stock Quotes Halozyme Therapeutics, Inc.|HALO - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Halozyme Therapeutics, Inc.|HALO - Total Company Value
- company book value details:
Equity per Share Halozyme|HALO - Book Capitalization|Market Cap to Net Assets Ratio halozyme.com|HALO - Company Total Assets
- company liabilities and liquidity data:
Debt to Capital Halozyme Therapeutics|HALO - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital halozyme.com|HALO - Company Total Debt|Debt to Net Assets Ratio Halozyme Therapeutics, Inc.|HALO - Company Long-Term Debts|Company Current Liabilities Halozyme|Quick Ratio halozyme.com
- financial results and valuation multiples details:
HALO - Company Net Income
General company analysis:Halozyme Therapeutics, Inc. - HALO
Original product of halozyme.com

The long-term debt-to-equity ratio measures the proportion of liabilities with a maturity exceeding one year within the equity structure, determining the business's level of dependence on external borrowing. Analyzing the current long-term debt-to-equity figure allows for an assessment of the financial stability of Halozyme Therapeutics (HALO), whose partner royalty model minimizes bankruptcy risks even amidst disruptions in international supply chains.

Key competitors

Long-Term Debt to Equity Ratio BeiGene Ltd. (ONC)|Long-Term Debt to Capital RVMD|Long-Term Debt to Capital Ascentage Pharma Corp (AAPG)|Long-Term Debt to Equity CG Oncology, Inc. CGON|URGN: Long-Term Debt to Capital Ratio|Bicara Therapeutics - Long-Term Debt to Capital|Personalis Inc (PSNL) - Long-Term Debt to Equity Ratio|ERAS: Long-Term Debt to Capital|Long-Term Liabilities to Capital Delcath Corp (DCTH)|Long-Term Debt to Equity Y-mAbs Therapeutics|AURA: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio CADL (Candel Therapeutics)|ARAY (Accuray Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital SLS (SELLAS Life Sciences Group)|ACTU - Long-Term Debt to Equity Ratio|CTOR: Long-Term Debt to Equity Ratio|HURA - Long-Term Debt to Capital|Protara Therapeutics, Inc. (TARA) - Long-Term Debt to Equity|Fate Therapeutics Inc - Long-Term Debt to Capital Coefficient|WHWK (Aadi Bioscience, Inc.) - Long-Term Debt to Capital|Long-Term Liabilities to Capital TScan TCRX|Long-Term Debt to Capital CSBR|XBIT (xbiotech.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital CVM (CEL-SCI)|Long-Term Debt to Capital OS Therapies Inc. OSTX|RADX - Long-Term Debt to Equity|ARTV: Long-Term Debt to Equity|adlainortye.com (ANL) - Long-Term Debt to Equity|Long-Term Liabilities to Capital verupharma.com (VERU)|Long-Term Debt to Equity Ratio TPST|Xilio - Long-Term Liabilities to Equity|Long-Term Debt to Equity Ratio RENB (Renovaro Inc.)|MURA - Long-Term Liabilities to Capital|Long-Term Debt to Equity Kairos Pharma KAPA|OKUR - Long-Term Debt to Equity Ratio|CytoMed - Long-Term Debt to Capital|Long-Term Liabilities to Capital Curis, Inc.|APLM (apollomicsinc.com) - Long-Term Debt to Equity Ratio|Tharimmune Corporation - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio ADVB|GNPX (genprex.com) - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital CLDI|SBFM (Sunshine Biopharma Inc.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital XBIO (Xenetic Biosciences, Inc.)|Salarius Pharma (SLRX) - Long-Term Liabilities to Capital|PPBT - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient AONC (American Oncology Network)|BGNE: Long-Term Debt to Capital|Checkpoint Therapeutics Inc. (CKPT) - Long-Term Debt to Capital|Long-Term Debt to Equity Elevation Oncology, Inc.|iCAD Corp - Long-Term Liabilities to Equity|Long-Term Debt to Capital IKNA|NTBL - Long-Term Liabilities to Capital|Viracta Therapeutics, Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital MorphoSys Inc MOR|NAYA: Long-Term Debt to Equity Ratio|Ascentage - Long-Term Loans to Capital Ratio